ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

U. Knigge; J. Capdevila; D. K. Bartsch; E. Baudin; J. Falkerby; R. Kianmanesh; B. Kos-Kudla; B. Niederle; E. Nieveen Van Dijkum; D. O'Toole; A. Pascher; N. Reed; A. Sundin; M. P. Vullierme; all other  Antibes Consensus Conference participants

doi:10.1159/000458155

ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

U. Knigge, J. Capdevila, D. K. Bartsch, E. Baudin, J. Falkerby, R. Kianmanesh, B. Kos-Kudla, B. Niederle, E. Nieveen Van Dijkum, D. O'Toole, A. Pascher, N. Reed, A. Sundin, M. P. Vullierme, all other Antibes Consensus Conference participants

Department of Clinical Medicine

39 Citations (Scopus)

Abstract

ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.

Original language	English
Journal	Neuroendocrinology
Volume	105
Issue number	3
Pages (from-to)	310-319
Number of pages	10
ISSN	0028-3835
DOIs	https://doi.org/10.1159/000458155
Publication status	Published - Sept 2017

Keywords

5-Hydroxyindoleacetic acid
Chromogranin A
Follow-up
Functional imaging
Neuroendocrine carcinoma
Neuroendocrine neoplasm
Neuroendocrine tumor
Neuron-specific enolase
NT-pro-brain natriuretic peptide
Somatostatin receptor imaging
TNM staging

Access to Document

10.1159/000458155

Cite this

Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen Van Dijkum, E., O'Toole, D., Pascher, A., Reed, N., Sundin, A., Vullierme, M. P., & all other Antibes Consensus Conference participants (2017). ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology, 105(3), 310-319. https://doi.org/10.1159/000458155

Knigge, U, Capdevila, J, Bartsch, DK, Baudin, E, Falkerby, J, Kianmanesh, R, Kos-Kudla, B, Niederle, B, Nieveen Van Dijkum, E, O'Toole, D, Pascher, A, Reed, N, Sundin, A, Vullierme, MP & all other Antibes Consensus Conference participants 2017, 'ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation', Neuroendocrinology, vol. 105, no. 3, pp. 310-319. https://doi.org/10.1159/000458155

@article{344a93dcd7d040b791229c10916abfd7,

title = "ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation",

abstract = "ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.",

keywords = "5-Hydroxyindoleacetic acid, Chromogranin A, Follow-up, Functional imaging, Neuroendocrine carcinoma, Neuroendocrine neoplasm, Neuroendocrine tumor, Neuron-specific enolase, NT-pro-brain natriuretic peptide, Somatostatin receptor imaging, TNM staging",

author = "U. Knigge and J. Capdevila and Bartsch, {D. K.} and E. Baudin and J. Falkerby and R. Kianmanesh and B. Kos-Kudla and B. Niederle and {Nieveen Van Dijkum}, E. and D. O'Toole and A. Pascher and N. Reed and A. Sundin and Vullierme, {M. P.} and {all other Antibes Consensus Conference participants}",

year = "2017",

month = sep,

doi = "10.1159/000458155",

language = "English",

volume = "105",

pages = "310--319",

journal = "Neuroendocrinology",

issn = "0028-3835",

publisher = "S Karger AG",

number = "3",

}

TY - JOUR

T1 - ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms

T2 - Follow-Up and Documentation

AU - Knigge, U.

AU - Capdevila, J.

AU - Bartsch, D. K.

AU - Baudin, E.

AU - Falkerby, J.

AU - Kianmanesh, R.

AU - Kos-Kudla, B.

AU - Niederle, B.

AU - Nieveen Van Dijkum, E.

AU - O'Toole, D.

AU - Pascher, A.

AU - Reed, N.

AU - Sundin, A.

AU - Vullierme, M. P.

AU - all other Antibes Consensus Conference participants

PY - 2017/9

Y1 - 2017/9

N2 - ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.

AB - ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.

KW - 5-Hydroxyindoleacetic acid

KW - Chromogranin A

KW - Follow-up

KW - Functional imaging

KW - Neuroendocrine carcinoma

KW - Neuroendocrine neoplasm

KW - Neuroendocrine tumor

KW - Neuron-specific enolase

KW - NT-pro-brain natriuretic peptide

KW - Somatostatin receptor imaging

KW - TNM staging

U2 - 10.1159/000458155

DO - 10.1159/000458155

M3 - Comment/debate

C2 - 28222443

AN - SCOPUS:85013636507

SN - 0028-3835

VL - 105

SP - 310

EP - 319

JO - Neuroendocrinology

JF - Neuroendocrinology

IS - 3

ER -

ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

Abstract

Keywords

Access to Document

Fingerprint

Cite this